Abstract

The bispecific therapeutic antibody blinatumomab links CD3+ cytotoxic T-cells to CD19+ B-cells, including B-cell acute lymphoblastic leukemia (ALL)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call